Can a reduced-intensity drug combo tame high-risk myeloma in frail older patients?

NCT ID NCT07732712

Not yet recruiting Disease control Sponsor: The Affiliated People's Hospital of Ningbo University Source: ClinicalTrials.gov ↗

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This trial tests whether a combination of isatuximab plus a reduced-intensity version of standard chemotherapy (VRDlite) can effectively treat newly diagnosed multiple myeloma in frail older adults who are not candidates for a stem cell transplant. The study focuses on patients with a high-risk form of the disease identified by circulating plasma cells in the blood. Researchers will measure how well the cancer responds and how safely the treatment can be given.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: isatuximab plus reduced-intensity bortezomib, lenalidomide, and dexamethasone (VRDlite)
What this could lead to: If successful, this could offer a more tolerable treatment option for frail older adults with high-risk multiple myeloma who cannot undergo a stem cell transplant.
What could go wrong: This is a small, early-phase trial with only 15 participants, so results may not apply to a broader population. The combination therapy may still cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.